Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector

被引：81

作者：

Ramírez, JC ^{[1
]}

Gherardi, MM ^{[1
]}

Rodríguez, D ^{[1
]}

Esteban, M ^{[1
]}

机构：

[1] CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, E-28049 Madrid, Spain

来源：

JOURNAL OF VIROLOGY | 2000年 / 74卷 / 16期

关键词：

D O I：

10.1128/JVI.74.16.7651-7655.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

A problem associated with the use of vaccinia virus recombinants as vaccines is the existence of a large human population with preexisting immunity to the vector. Here we showed that after a booster with attenuated recombinant modified vaccinia virus Ankara (rMVA), higher humoral and cellular immune responses to foreign antigens (human immunodeficiency virus type 1 Env and beta-galactosidase) were found in mice preimmunized with rMVA than in mice primed with the virulent Western Reserve strain and boosted with rMVA. This enhancement correlated with higher levels of expression of foreign antigens after the booster.

引用

页码：7651 / 7655

页数：5

共 24 条

[1] Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity [J].

Belyakov, IM ;

Moss, B ;

Strober, W ;

Berzofsky, JA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4512-4517

[2] ENHANCED IMMUNITY TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) ENVELOPE ELICITED BY A COMBINED VACCINE REGIMEN CONSISTING OF PRIMING WITH A VACCINIA RECOMBINANT EXPRESSING HIV ENVELOPE AND BOOSTING WITH GP160-PROTEIN [J].

COONEY, EL ;

MCELRATH, MJ ;

COREY, L ;

HU, SL ;

COLLIER, AC ;

ARDITTI, D ;

HOFFMAN, M ;

COOMBS, RW ;

SMITH, GE ;

GREENBERG, PD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (05) :1882-1886

[3] SAFETY OF AND IMMUNOLOGICAL RESPONSE TO A RECOMBINANT VACCINIA VIRUS-VACCINE EXPRESSING HIV ENVELOPE GLYCOPROTEIN [J].

COONEY, EL ;

COLLIER, AC ;

GREENBERG, PD ;

COOMBS, RW ;

ZARLING, J ;

ARDITTI, DE ;

HOFFMAN, MC ;

HU, SL ;

COREY, L .

LANCET, 1991, 337 (8741) :567-572

[4]

COX WI, 1992, RECOMBINANT POXVIRUS, P123

[5] VACCINIA VIRUS RECOMBINANT EXPRESSING HERPES-SIMPLEX VIRUS TYPE-1 GLYCOPROTEIN-D PREVENTS LATENT HERPES IN MICE [J].

CREMER, KJ ;

MACKETT, M ;

WOHLENBERG, C ;

NOTKINS, AL ;

MOSS, B .

SCIENCE, 1985, 228 (4700) :737-740

[6] HUMORAL IMMUNE-RESPONSE ELICITED BY HIGHLY ATTENUATED VARIANTS OF VACCINIA VIRUS AND BY AN ATTENUATED RECOMBINANT EXPRESSING HIV-1 ENVELOPE PROTEIN [J].

DALLO, S ;

MAA, JS ;

RODRIGUEZ, JR ;

RODRIGUEZ, D ;

ESTEBAN, M .

VIROLOGY, 1989, 173 (01) :323-329

[7] CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX-RESTRICTED CYTOTOXIC T-CELL RESPONSES TO VACCINIA VIRUS IN HUMANS [J].

ERICKSON, AL ;

WALKER, CM .

JOURNAL OF GENERAL VIROLOGY, 1993, 74 :751-754

[8] OVERCOMING INHIBITION OF ANTIBODY-RESPONSES TO A MALARIA RECOMBINANT VACCINIA VIRUS CAUSED BY PRIOR EXPOSURE TO WILD-TYPE VIRUS [J].

ETLINGER, HM ;

ALTENBURGER, W .

VACCINE, 1991, 9 (07) :470-472

[9] SUCCESSFUL VACCINATION WITH A POLYVALENT LIVE VECTOR DESPITE EXISTING IMMUNITY TO AN EXPRESSED ANTIGEN [J].

FLEXNER, C ;

MURPHY, BR ;

ROONEY, JF ;

WOHLENBERG, C ;

YUFEROV, V ;

NOTKINS, AL ;

MOSS, B .

NATURE, 1988, 335 (6187) :259-262

[10] Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants [J].

Gherardi, MM ;

Esteban, M .

VACCINE, 1999, 17 (9-10) :1074-1083

← 1 2 3 →